Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|May 2, 2015
- Pharmaceutical Technology-05-02-2015
- Volume 39
- Issue 5
Ross Disperser Increases Versatility
Ross’ HSM-100LH-3 Vacuum High Speed Disperser is designed for up to five gallons of laboratory and pilot-scale mixing.
Ross’ HSM-100LH-3 Vacuum High Speed Disperser is designed for up to five gallons of laboratory and pilot-scale mixing. The disperser can be equipped with a heating/cooling jacket, mixer cover with sight/charge ports, and a vacuum-rated mix vessel. The mixer is designed with interchangeable saw-tooth disperser blades in various sizes including 2-, 3-, 3.5-, and 4-inch diameters, with speeds up to 4800 rpm and turnover of viscosities of up to 50,000 centipoise.
A three horsepower (3HP) variable frequency drive-rated motor operates the mixer, with safety limit switches that prevent operation of the mixer in the raised position or without a mix vessel in place. Single point electrical hook-up is possible with a 3HP inverter that is mounted to the mixer and wired to the motor and limit switches. An air/oil hydraulic lift enables the mixing head to be raised with pushbutton controls.
Ross, Charles & Son Company
Articles in this issue
over 11 years ago
Transdermal Drug Delivery Gains Tractionover 11 years ago
Biomanufacturing Outsourcing Globalization Continuesover 11 years ago
How to Stay Abreast of Shifting Regulations and Remain Compliantover 11 years ago
Considering Continuous Crystallizationover 11 years ago
Fixing Tableting Problemsover 11 years ago
Ensuring the Quality of Biologicalsover 11 years ago
Planning for the Future of Serializationover 11 years ago
Streamlining Raw Materials Testingover 11 years ago
Industry Expert Q&A with Matt Hicksover 11 years ago
UV Laser Marking System Ensures Permanent MarkingRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.